Collegium Pharmaceutical, Inc. (COLL)

Market Cap	1.10B +26.1%
Revenue (ttm)	796.33M +19.9%
Net Income	74.95M +70.8%
EPS	1.64 +30.7%
Shares Out	32.43M
PE Ratio	20.72
Forward PE	4.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,165
Open	33.77
Previous Close	33.65
Day's Range	33.44 - 34.15
52-Week Range	28.34 - 50.79
Beta	0.76
Analysts	Buy
Price Target	54.33 (+60.5%)
Earnings Date	May 7, 2026

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.

Analyst Summary

According to 6 analysts, the average rating for COLL stock is "Buy." The 12-month stock price target is $54.33, which is an increase of 60.50% from the latest price.

Price Target

$54.33

(60.50% upside)

Analyst Consensus: Buy